ライフサイエンスコーパス: dependent kinase

1 dependent on CDK7, a transcriptional cyclin-dependent kinase.

2 e Cdc37 is essential for activation of Hsp90-dependent kinases.

3 s, could potentially be substrates of cyclin-dependent kinases.

4 cription may be directly regulated by cyclin-dependent kinases.

5 on mediated by signaling pathways and cyclin-dependent kinases.

6 peptides that bind to a subset of the cyclin-dependent kinases.

7 physiological conditions, we show how cyclin-dependent kinase 1 (CDK1) activates the APC/C through co

8 of ATR ablation is not due to altered cyclin-dependent kinase 1 (CDK1) activity, DNA damage responses

9 promote actin cable assembly through cyclin-dependent kinase 1 (Cdk1) activity.

10 hosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1) at Ser(119) and Ser(175) durin

11 Phosphorylation by Cyclin-dependent kinase 1 (CDK1) at two conserved sites in this

12 hosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1) during antimitotic drug-induce

13 Here, we report that NSun2 regulates cyclin-dependent kinase 1 (CDK1) expression in a cell cycle-dep

14 During mitosis, cyclin-dependent kinase 1 (CDK1) substitutes for mTOR and fully

15 totic activation of Gwl requires both cyclin-dependent kinase 1 (CDK1)-dependent phosphorylation and

16 Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of RE

17 lation of hundreds of proteins by the cyclin-dependent kinase 1 (Cdk1):cyclin B (CycB) complex.

18 dylinositol 3-kinase (PI3K)/phosphoinositide-dependent kinase 1 (PDK1) pathway.

19 RK and are activated by phosphatidylinositol-dependent kinase 1 (PDK1) phosphorylating T(308) before

20 ading to PI3K activation of phosphoinositide-dependent kinase 1 (PDK1).

21 kt/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3

22 hat mice lacking the kinase phosphoinositide-dependent kinase 1 selectively lack LC.

23 nase kinase, ribosomal S6 kinase, and cyclin-dependent kinase 1/2 in combination with Bcl-XL inhibiti

24 This activates cyclin-dependent kinase 1/cyclin B1 (CDK1/CYCB1) to directly hy

25 ATR (ATM and Rad3-related) and by the cyclin-dependent kinases 1 and 2.

26 , in which phosphorylated 3-phosphoinositide-dependent kinase-1 (p-PDK1) is increased in response to

27 Previously, we have found that cyclin-dependent kinase 11 (CDK11) signaling was essential for

28 orylation (activation) of calcium/calmodulin-dependent kinase 2 (CaMKII) and also that inhibition of

29 and redox-sensing enzyme Ca(2+) /calmodulin-dependent kinase 2 (CaMKII) is a crucial and well-establ

30 single-cell time-lapse microscopy of Cyclin-Dependent Kinase 2 (CDK2) activity followed by endpoint

31 nE1) is the regulatory subunit of the cyclin-dependent kinase 2 (Cdk2) and controls cell cycle re-ent

32 cell cycle, elevation of Cylin E and Cyclin-dependent kinase 2 (CDK2) and downregulation of p21, p27

33 Cyclin-dependent kinase 2 (CDK2) is a known regulator in the ce

34 lated, levels of p27 are reduced, and cyclin-dependent kinase 2 (CDK2) is activated upon SIRT1 reduct

35 ecific PTPN12-insert-loop harboring a cyclin-dependent kinase 2 (CDK2) phosphorylation site.

36 e show that the cell cycle regulator, cyclin-dependent kinase 2 (CDK2), couples primary beta-cell dys

37 Expression of the cyclin-dependent kinase 2 (CDK2), itself a downstream target of

38 onjunction with its catalytic partner cyclin-dependent kinase 2 (CDK2), regulates cell cycle progress

39 ha-helical structure, upon binding to cyclin-dependent kinase 2 (Cdk2)/cyclin A.

40 yclin E and its co-activator, phospho-cyclin-dependent kinase 2 (p-CDK2), regulate G1 to S phase tran

41 m progression through the cell cycle (cyclin-dependent kinase 2 activity).

42 p27, reduced cyclin A1 and attenuated cyclin-dependent kinase 2 activity.

43 f protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncog

44 rogression of DN, downregulated CDK2 (cyclin-dependent kinase 2).

45 Cyclin D1/D3 and cyclin-dependent kinase 2/4 (cdc2/cdc4) were downregulated and

46 orylation is driven by the actions of cyclin-dependent kinases 2 and 4/6 at G1/S cell-cycle checkpoin

47 rotein levels of cyclins (D1, E1) and cyclin-dependent kinases (2, 4, and 6).

48 Reporter gene assays revealed cyclin-dependent kinase 3 (CDK3) as a direct target of miR-873.

49 ammalian two-hybrid assay showed that cyclin-dependent kinase 3 (CDK3) directly interacted with NFAT3

50 mplification of chromosome 12q13-q15 (Cyclin-dependent kinase 4 (CDK4) amplicon) is frequently observ

51 Cyclin D and cyclin-dependent kinase 4 (cdk4) are overexpressed in a variety

52 d to analyze the participation of the cyclin-dependent kinase 4 (CDK4) in adipose tissue biology.

53 et different immunogenic mutations in cyclin-dependent kinase 4 (CDK4) that naturally occur in human

54 was mediated by the neo-expression of cyclin-dependent kinase 4 (CDK4).

55 ecreased the expression of cyclin D1, cyclin dependent kinase 4 and 6, and increased the expression o

56 tivated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.

57 hat may be due to an effect of p16 on cyclin-dependent kinase 4 levels and IL-12 secretion by DC.

58 induction of the INK4 (inhibitors of cyclin dependent kinase 4) locus leading to cell-cycle arrest.

59 mplified tumours and a combination of cyclin-dependent kinase 4/6 (CDK4/6) and EGFR inhibitors preven

60 n FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation-induce

61 notype was reversed by treatment with cyclin-dependent kinase 4/6 inhibitor, PD0332991/palbociclib, t

62 ation of a MEK inhibitor with PI3K or cyclin-dependent kinase 4/6 inhibitors.

63 Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drive

64 We identify cyclin-dependent kinases 4 and 6 (CDK4/6) as essential regulato

65 The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially ove

66 Cyclin-dependent kinases 4 and 6 (CDK4/6) drive progression thr

67 Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibi

68 The cyclin-dependent kinase 5 (CDK-5) activating protein, p35, is i

69 content decreases after inhibition of cyclin-dependent kinase 5 (Cdk5) and ERK1/2.

70 Furthermore, Cadm4, cyclin-dependent kinase 5 (Cdk5) and p39 mRNAs were significant

71 is inhibited upon phosphorylation by cyclin-dependent kinase 5 (Cdk5) at Thr345.

72 uires tightly regulated activation of Cyclin-dependent kinase 5 (Cdk5) by two distinct cofactors, p35

73 PKs and proline-directed kinases like cyclin-dependent kinase 5 (Cdk5) in cell-based as well as in vi

74 ntly identified an essential role for cyclin-dependent kinase 5 (Cdk5) in T-cell activation and effec

75 Here, we show that cyclin-dependent kinase 5 (Cdk5) is an essential regulator of l

76 re, we report for the first time that cyclin-dependent kinase 5 (Cdk5) is an essential regulator of M

77 Here we show that cyclin-dependent kinase 5 (Cdk5) is required for dbcAMP and put

78 gorithm, we showed that inhibition of Cyclin-dependent kinase 5 (Cdk5) led to reduced branching in th

79 Dysregulation of cyclin-dependent kinase 5 (cdk5) per relative concentrations of

80 Cyclin-dependent kinase 5 (CDK5) phosphorylated DRP1 to increas

81 elination, including the noncanonical cyclin-dependent kinase 5 (Cdk5) whose functions are regulated

82 Here, we show that cyclin-dependent kinase 5 (Cdk5), a serine-threonine kinase tha

83 Cyclin-dependent kinase 5 (Cdk5), which binds to and is activat

84 known to induce aberrant activity of cyclin-dependent kinase 5 (Cdk5), which is associated with neur

85 , p35 and p39, independently activate Cyclin-dependent kinase 5 (Cdk5), which plays diverse roles in

86 activity-dependent phosphorylation by cyclin-dependent kinase 5 (Cdk5).

87 14; P<0.05), and significantly higher cyclin-dependent kinase 5 activity (n=4; P<0.001).

88 s of p25/p35, indicative of increased cyclin-dependent kinase 5 activity as compared with wild-type (

89 enhanced by prior phosphorylation by cyclin-dependent kinase 5 and antagonized by Fyn phosphorylatio

90 phamine treatment was shown to reduce cyclin-dependent kinase 5 in patient cells, suggesting a conver

91 oscovitine and siRNA directed towards cyclin-dependent kinase 5) ameliorated the cilia phenotype.

92 one modifications at the murine Cdk5 (cyclin-dependent kinase 5) locus, given growing evidence of Cdk

93 ccompanied by generation of the Cdk5 (cyclin-dependent kinase 5)-activator p25, up-regulation and pho

94 h the phosphatase PP2A and the kinase cyclin-dependent kinase 5.

95 throid 2-related factor 2, notch, and cyclin-dependent kinase 5.

96 in, and was opposed by the actions of cyclin-dependent kinase 5.

97 tivation and downstream activation of cyclin-dependent kinase 6 (Cdk6) and MycNol3(-/-) MPN Thy1(+)LS

98 ay be mediated by targeting of HMGA2, cyclin-dependent kinase 6 (CDK6), and other predicted miR-33b t

99 ulation of its proven targets, namely cyclin-dependent kinase 6 and Mcl1.

100 lar, to THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7).

101 that the Mediator-associated kinases cyclin-dependent kinase 8 (CDK8) and CDK19 restrain increased a

102 It binds to cyclin-dependent kinase 8 (CDK8) and enhances its kinase activi

103 e identify the Skp2-macroH2A1 (mH2A1)-cyclin-dependent kinase 8 (CDK8) axis as a critical pathway for

104 kinase module, which contains either cyclin-dependent kinase 8 (CDK8) or CDK19.

105 Mechanistically, BRD4 is required for cyclin-dependent kinase 9 (CDK9) recruitment and phospho-Ser 2

106 e enhancer regions, and inhibition of cyclin-dependent kinase 9 (CDK9), that regulates these elongati

107 ontaining 4 (BRD4) with NF-kappaB and cyclin-dependent kinase 9 (CDK9).

108 itors of the transcription regulating cyclin-dependent kinase 9 on the development and progression of

109 ed at an N-terminal serine cluster by cyclin-dependent kinase-9 (CDK9), which is recruited into GC-in

110 tion of the core cell cycle regulator CYCLIN-DEPENDENT KINASE A;1 (CDKA;1) and that this repression i

111 al two-step mechanism in which 1) the cyclin-dependent kinase activating kinase Cak1 phosphorylaytes

112 ls for 3 months and found that sustained AMP-dependent kinase activation improved cytochrome c oxidas

113 with PI3Ks and blocks activation of the PI3K-dependent kinase AKT following binding of growth factor

114 his study was to evaluate the role of an AMP-dependent kinase (AMPK) activator, 5-aminoimidazole-4-ca

115 P-TEFb comprises the Cdk9 cyclin-dependent kinase and a cyclin T.

116 Cdc25A dephosphorylates cyclin-dependent kinase and regulates the cell cycle, but other

117 ated by both the CDC7-Dbf4 kinase and cyclin-dependent kinase and via interactions with CDC45 and go-

118 esults reveal that mTOR is a new type of CaM-dependent kinase, and TRPML1, lysosomal calcium and CaM

119 upregulation of p21, an inhibitor of cyclin-dependent kinases, and blocked G1 arrest after TBI there

120 revents nucleolar release of the Cdk (Cyclin-dependent kinase)-antagonising phosphatase Cdc14 by coun

121 es are not phosphorylated properly by cyclin-dependent kinase/CDC7-Dbf4 kinase and exhibit reduced DN

122 kinase phosphorylates and inactivates cyclin-dependent kinase (Cdk) 1/2 in response to DNA damage.

123 ociclib is a potent and specific oral cyclin-dependent kinase (CDK) 4/6 inhibitor that has strong pre

124 inking cell growth and two sequential cyclin dependent kinase (CDK) activities, and experimental resu

125 70 to promote NHEJ in G1 when overall cyclin-dependent kinase (CDK) activity is low.

126 s ordered by thresholds of increasing cyclin-dependent kinase (Cdk) activity.

127 s controlled during the cell cycle by cyclin-dependent kinase (CDK) and Dbf4-dependent kinase (DDK),

128 During mitosis, cyclin-dependent kinase (Cdk) and polo-like kinase (Plk) contro

129 urther required to promote loading of cyclin-dependent kinase (CDK) and proliferating cell nuclear an

130 demonstrated for other substrates, as cyclin-dependent kinase (CDK) binding-defective mutants are cap

131 Cyclin D-CDK4/6 are the first cyclin-dependent kinase (CDK) complexes to be activated by mito

132 T387 lies in a cyclin-dependent kinase (CDK) consensus sequence, and CDK inhib

133 cycling after nutrient deprivation or cyclin-dependent kinase (CDK) inactivation express HO in the fi

134 tablishing cell cycle control through cyclin-dependent kinase (CDK) inhibition has therefore emerged

135 The cyclin-dependent kinase (CDK) inhibitor 1A, p21/Cip1, is a vita

136 Cyclin-dependent kinase (CDK) inhibitor drugs induce neutrophil

137 investigated the regulation of p21, a cyclin-dependent kinase (CDK) inhibitor encoded by CDKN1A, in H

138 The levels of the cyclin-dependent kinase (CDK) inhibitor p21 are low in S phase

139 27 results in increased levels of the cyclin-dependent kinase (CDK) inhibitor p21(Cip1).

140 sponsive downstream proteins, such as cyclin-dependent kinase (CDK) inhibitor p21, which promotes cel

141 The cyclin-dependent kinase (CDK) inhibitor p27(kip1) is a critical

142 ilizes and increases the level of the cyclin-dependent kinase (CDK) inhibitor p27, which inhibits cel

143 OR inhibition blunts the induction of cyclin-dependent kinase (CDK) inhibitors (CDKIs), including p16

144 Cyclin dependent kinase (CDK) inhibitors have been the topic of

145 The Cip/Kip family of cyclin-dependent kinase (Cdk) inhibitors includes p21(Cip1), p2

146 activity, increased expression of the cyclin-dependent kinase (CDK) inhibitors p16INK4A (CDKN2A) and

147 apoptotic cascades, up-regulation of cyclin-dependent kinase (CDK) inhibitors p21 and p27, and inhib

148 Since cyclin-dependent kinase (CDK) inhibitors, CDKN2A and CDKN2B, an

149 could be attenuated by treatment with cyclin-dependent kinase (CDK) inhibitors.

150 arrested because of the expression of cyclin-dependent kinase (CDK) inhibitors.

151 nd tensin homolog/AKT, retinoblastoma/cyclin-dependent kinase (CDK) N2A-p16(INK4A), and TP53/mouse do

152 urthermore, our analyses identified a cyclin-dependent kinase (CDK) signaling node that, when targete

153 iation factor and essential target of Cyclin-Dependent Kinase (CDK), are targets of the checkpoint ki

154 in vivo accumulate p27(Cdkn1b), show cyclin-dependent kinase (Cdk)-1 inhibition, retain their LFC nu

155 ivation loop is phosphorylated by the cyclin-dependent kinase (CDK)-activating kinase (Cak1), and Y20

156 stead, the T is phosphorylated by the cyclin-dependent kinase (CDK)-activating kinase, Cak1.

157 monstrate that Ngn3 protein undergoes cyclin-dependent kinase (Cdk)-mediated phosphorylation on multi

158 Cellular cyclin-dependent kinase (CDK)-mediated Rb inactivation through

159 ctivated during cell cycle transit by cyclin-dependent kinase (Cdk)-mediated Rb phosphorylation.

160 counterbalance its phosphorylation by cyclin-dependent kinase (Cdk).

161 ine 118 (Ser118) by the TFIIH kinase, cyclin-dependent kinase (CDK)7.

162 ere highly sensitive to inhibitors of cyclin-dependent kinases (CDK), especially THZ1, a covalent inh

163 el potent small molecule inhibitor of cyclin-dependent kinases (CDK)1, CDK2, CDK5, and CDK9.

164 otein kinase Wee1, which inhibits the cyclin-dependent kinase Cdk1 in yeast through human cells.

165 The activity of cyclin-dependent kinase Cdk1 is essential for DSB repair by hom

166 Cyclin A2 activates the cyclin-dependent kinases Cdk1 and Cdk2 and is expressed at elev

167 ics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies.

168 Cyclin-dependent kinase (Cdk1) orchestrates progression through

169 rbon metabolism are controlled by the cyclin-dependent kinase (Cdk1), a major cell cycle regulator, a

170 ll cycle and is tightly controlled by cyclin-dependent kinase (Cdk1).

171 ced phosphorylation of its substrate, cyclin-dependent kinase (Cdk1).

172 of transcription (Tat) as well as the cyclin-dependent kinases CDK13 and CDK11 and positive transcrip

173 ed using a bioinformatics strategy as cyclin-dependent kinases CDK2 and CDK9 inhibitors, which play c

174 ere, we report that activation of the cyclin-dependent kinases CDK4 and CDK6 are essential and suffic

175 ibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially improve pr

176 (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components of the

177 Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S

178 nctions by binding to, and activating cyclin-dependent kinase, CDK7, which regulates transcription by

179 The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disea

180 The mediator complex-associated cyclin dependent kinase CDK8 regulates beta-catenin-dependent t

181 ctylum tricornutum, by binding to two cyclin-dependent kinases, CDKA1 and CDKA2.

182 actor TRF2 within the promoter of the cyclin-dependent kinase CDKNIA (p21/CIP1/WAF1).

183 horylation by the "early" cyclins and cyclin-dependent kinases (cdks) (d-cyclins cdk4/6) and the "lat

184 an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical eviden

185 is strictly controlled by a number of cyclin-dependent kinases (CDKs) and CDK inhibitors (CKIs), the

186 of hundreds of different proteins by cyclin-dependent kinases (CDKs) and other kinases.

187 The antagonism between cyclin-dependent kinases (Cdks) and the ubiquitin ligase APC/C-

188 Cyclin-dependent kinases (CDKs) and their associated regulatory

189 eukaryotic cell cycle progression are cyclin-dependent kinases (CDKs) and their partners.

190 Cyclins and cyclin-dependent kinases (CDKs) are hyperactivated in numerous

191 Increasing evidence suggests that cyclin-dependent kinases (Cdks) are inappropriately activated i

192 Cyclin-dependent kinases (Cdks) are principal drivers of cell d

193 Upon DNA damage, cyclin-dependent kinases (CDKs) are typically inhibited to bloc

194 Cyclin-dependent kinases (CDKs) control cell division in eukary

195 Cyclin-dependent kinases (CDKs) coordinate cell cycle checkpoin

196 Aberrant activation of cyclin-dependent kinases (CDKs) has been shown to contribute to

197 inoblastoma-related (RBR) proteins by cyclin-dependent kinases (CDKs) is well documented, but the cou

198 Furthermore, we show that cyclin-dependent kinases (CDKs) phosphorylate PAH1 at serine 16

199 Cyclin-dependent kinases (CDKs) play key roles in cell cycle re

200 Transcriptional cyclin-dependent kinases (CDKs) regulate RNA polymerase II init

201 hmania mexicana has a large family of cyclin-dependent kinases (CDKs) that reflect the complex interp

202 ity is blocked by compounds targeting cyclin-dependent kinases (CDKs), as well as by dominant-negativ

203 cyclins that act in association with cyclin-dependent kinases (CDKs).

204 ated at discrete transition points by cyclin-dependent kinases (CDKs).

205 Eukaryotic cell division is driven by cyclin-dependent kinases (CDKs).

206 rk asymmetry, and increased levels of cyclin-dependent kinases (CDKs).

207 uced two cellular responses involving cyclin-dependent kinases (CDKs).

208 ion in response to activation of AKT and AMP-dependent kinase [corrected].

209 MOTING COMPLEX SUBUNIT 10 (APC10) and CYCLIN-DEPENDENT KINASE D (CDKD) proteins from the proliferatio

210 Dbf4-dependent kinase (DDK) and S-phase cyclin-dependent kina

211 timulate the phosphorylation of Mcm2 by Dbf4-dependent kinase (DDK) in vitro.

212 Here we show that mutations of Dbf4-dependent kinase (DDK) of Saccharomyces cerevisiae, but

213 Dbf4-dependent kinase (DDK) phosphorylates minichromosome mai

214 Dbf4-dependent kinase (DDK) promotes replication by phosphory

215 One of these binding partners is the Dbf4-dependent kinase (DDK), a heterodimer composed of the Cd

216 le by cyclin-dependent kinase (CDK) and Dbf4-dependent kinase (DDK), and in response to DNA damage by

217 d major cell-cycle kinase, Cdc7-Dbf4 or Dbf4-dependent kinase (DDK).

218 otein-E2F binding specificity and how cyclin-dependent kinases differentially regulate pocket protein

219 DNA-PKcs (the catalytic subunit of the DNA-dependent kinase, encoded by PRKDC), ATM (ataxia telangi

220 changes in substrate specificity during ADP-dependent kinase evolution along with the structural det

221 guanylyl cyclase-A (GC-A) receptor and cGMP-dependent kinase I (cGKI), strengthen systemic endotheli

222 used alpha subunit of the calcium/calmodulin-dependent kinase II (alphaCaMKII) mutant mice with alter

223 lated protein 1 (Drp1), by Ca(2+)/calmodulin-dependent kinase II (CaMKII) at a serine 616 (S616) site

224 nduced calcium signaling, calcium/calmodulin-dependent kinase II (CaMKII) phosphorylates OGT, which i

225 ends on the activation of calcium/calmodulin-dependent kinase II (CaMKII).

226 o Inhibiting PKC, JNK, or calcium/calmodulin-dependent kinase II activity prevented the effects of PK

227 phosphorylation event on calcium-calmodulin-dependent kinase II alpha (CaMKIIalpha) at serine (S)331

228 directly through JNK1 and calcium/calmodulin-dependent kinase II and also by inducing expression of P

229 sion also increases alpha-calcium/calmodulin-dependent kinase II protein expression, and this is asso

230 ynthesis of APP and alpha-calcium/calmodulin-dependent kinase II, a kinase that can phosphorylate tau

231 showed a decreased activation of Ca(2+)/CaM-dependent kinase II, most prominently the D129G CaM muta

232 optotic protein (c-IAP-2) through calmodulin-dependent kinase-II activation.

233 dicer, and a probable uncharacterized cyclin dependent kinase in honey bees, we utilized RNAi to redu

234 Here, we report that CRK1, a G1 cyclin-dependent kinase in Trypanosoma brucei, regulates antero

235 structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication.

236 Shh) pathway agonist purmorphamine or cyclin-dependent kinase inhibition (using roscovitine and siRNA

237 gnized convergence of Shh agonism and cyclin-dependent kinase inhibition as potential therapeutic tar

238 These include the cyclin-dependent kinase inhibitor (CDKI) p18INK4c, the master t

239 el of resistance to a pharmacological cyclin-dependent kinase inhibitor (CDKi), we show that this ass

240 how that polymersomes can deliver the cyclin-dependent kinase inhibitor (R)-roscovitine into human ne

241 genes, and we identified the mRNA of cyclin-dependent kinase inhibitor 1A (Cdkn1a, p21) as a direct

242 edly decreased quiescence and reduced cyclin-dependent kinase inhibitor 1b/c (Cdkn1b/1c) expression a

243 hosphatase and tensin homolog (PTEN), cyclin dependent kinase inhibitor 2A (CDKN2A), LKB1, and others

244 f knockdowns of the tumor suppressors cyclin-dependent kinase inhibitor 2A (Cdkn2a), transformation-r

245 microbial insult (e.g. LPSs) induces cyclin-dependent kinase inhibitor 2A (CDKN2A/p16(INK4a)) expres

246 ranscription, and thyroxine decreased cyclin-dependent kinase inhibitor 2A (p16(ink4)) expression in

247 beta (TGFbeta) signaling in cultured cyclin-dependent kinase inhibitor 2B (CDKN2B)-deficient cells,

248 es GC formation through repression of cyclin-dependent kinase inhibitor CDKN1A (p21(Cip1)).

249 sor, which leads to expression of the cyclin-dependent kinase inhibitor CDKN1A (p21(CIP1/WAF1)).

250 Using the cyclin-dependent kinase inhibitor dinaciclib, which downregulat

251 Two homologous cyclin-dependent kinase inhibitor genes, SIAMESE (SIM) and SIM-

252 alternative reading frame of the p16 cyclin-dependent kinase inhibitor INK4a/ARF gene.

253 e found that the expression of p21, a cyclin-dependent kinase inhibitor involved in cell cycle regula

254 functions specifically to bypass the cyclin-dependent kinase inhibitor p18(INK4c), revealing an unan

255 regulators cyclins D, A2, and B2 and cyclin-dependent kinase inhibitor p20 in brain tissue.

256 ccompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expression

257 The cyclin-dependent kinase inhibitor p21 is an important player in

258 deficiency promotes expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1) (Cdkn1a), a fa

259 creases transcription and activity of cyclin-dependent kinase inhibitor p21(WAF1/CIP1), leading to sp

260 receptors EGFR, ERBB3 (HER3), and the cyclin-dependent kinase inhibitor p27 (CDKN1B) was found to acc

261 translation of mRNAs encoding for the cyclin-dependent kinase inhibitor p27(Kip1) and antiapoptotic p

262 l proliferation by the destruction of cyclin-dependent kinase inhibitor p27(kip1), and deletion of p2

263 hich causes hyper-accumulation of the cyclin-dependent kinase inhibitor p27, leading to mitotic arres

264 ion of c-Myc and stabilization of the cyclin-dependent kinase inhibitor p27/KIP1.

265 entiation by modulating expression of cyclin-dependent kinase inhibitor p27/p57 and E3 ubiquitin liga

266 ndocrine therapy, with or without the cyclin-dependent kinase inhibitor palbociclib.

267 xpression of PDGFRbeta and p57kip2, a cyclin-dependent kinase inhibitor, in these cells.

268 cence by repressing the expression of cyclin-dependent kinase inhibitor, p21(Waf1/Cip1).

269 ity between a GHV cyclin and a single cyclin-dependent kinase inhibitor.

270 nd 6, and increased the expression of cyclin dependent kinase inhibitors (CDKIs), p21 and p27.

271 ss of signaling cargos and sequesters cyclin-dependent kinase inhibitors (CKIs) involved in ETI signa

272 ts and associated therapeutic agents: cyclin-dependent kinase inhibitors and poly(adenosine diphospha

273 wnstream targets, cJUN, ATF3, and the cyclin-dependent kinase inhibitors CDKN1A and CDKN2B.

274 nd demonstrate that silencing the cell cycle-dependent kinase inhibitors CDKN2C/p18 or CDKN1A/p21 fac

275 differential roles of two homologous cyclin-dependent kinase inhibitors in regulating cell-cycle pro

276 ion is due in part to derepression of cyclin-dependent kinase inhibitors Ink4a/b, while ineffective c

277 rrangement and release of sequestered cyclin-dependent kinase inhibitors to elicit immunity and death

278 host senescence response mediated by cyclin-dependent kinase inhibitors: p21(CIP1/WAF1) (p21) and p2

279 Ca(2+)/calmodulin-dependent kinase kinase beta (CaMKKbeta) emerges as a de

280 a a pathway that included calcium/calmodulin-dependent kinase kinase beta (CaMKKbeta), AMP-activated

281 Cyclin-dependent kinase-like 5 (CDKL5) deficiency is a neurodev

282 ing and memory.SIGNIFICANCE STATEMENT Cyclin-dependent kinase-like 5 (CDKL5) deficiency is a severe n

283 CDKL5 (cyclin-dependent kinase-like 5) is mutated in many severe neuro

284 GluA1 subunit of AMPAR by cyclic nucleotide-dependent kinases, making cyclic nucleotide phosphodiest

285 ing, which is negatively regulated by Cyclin-dependent kinase-mediated phosphorylation of segments fl

286 that combined inhibition of RAF and d-cyclin-dependent kinases might provide an effective approach to

287 Using the glycolytic ADP-dependent kinases of archaea, including the orders Therm

288 e investigated how phosphorylation by Cyclin-dependent kinase on distinct residues regulates p107 aff

289 The PI3K/phosphoinositide-dependent kinase (PDK) 1 pathway represents the canonica

290 his study, we show that in yeast, the cyclin-dependent kinase Pho85/CDK5 provides protection against

291 We find that protein kinase C and cyclin-dependent kinase phosphorylate ANG, enabling ANG to evad

292 s process through expression of the NFkappaB-dependent kinase proviral integration site for Moloney m

293 Loss of the adaptor protein cyclin-dependent kinase regulatory subunit 1 (Cks1), a cofactor

294 f4-dependent kinase (DDK) and S-phase cyclin-dependent kinase (S-CDK) are two S phase-specific kinase

295 hat Magnaporthe oryzae CKS1 encodes a cyclin-dependent kinase subunit, which plays a significant role

296 Cdk5 is an atypical cyclin-dependent kinase that is well characterized for its role

297 ctor 2 kinase (eEF2K) is a Ca(2+)/calmodulin-dependent kinase that regulates translation elongation b

298 members of the DUF1537 family are novel ATP-dependent kinases that participate in catabolic pathways

299 cytomegalovirus (HCMV)-encoded viral cyclin-dependent kinase (v-CDK) UL97 phosphorylates the retinob

300 and in cells where calmodulin and calmodulin-dependent kinase were blocked pharmacologically, S1P3 an